Brentuximab vedotin for the treatment of CD30+ lymphomas
- PMID: 21463188
- DOI: 10.2217/imt.11.15
Brentuximab vedotin for the treatment of CD30+ lymphomas
Abstract
Brentuximab vedotin is a novel antibody-drug conjugate consisting of the anti-CD30 antibody cAC10 chemically conjugated to monomethylauristatin E, a potent antimicrotubule agent. Preliminary response rates of 75% in relapsed/refractory Hodgkin's lymphoma and 87% in relapsed/refractory systemic anaplastic large-cell lymphoma were recently reported in large Phase II trials. Brentuximab vedotin is well tolerated with manageable side effects including peripheral sensory neuropathy. This antibody-drug conjugate is currently under investigation in numerous clinical trials, including in combination with front-line chemotherapy for high-risk Hodgkin's lymphoma and in a placebo-controlled, Phase III trial for patients with Hodgkin's lymphoma at high risk for residual disease following autologous stem cell transplant. The impressive response rates and limited toxicity of brentuximab vedotin are very promising for relapsed/refractory patients with few treatment options. In addition, the possibilities for incorporation into front-line therapies for both Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma are intriguing.
Similar articles
-
[Brentuximab vedotin: new treatment for CD30+ lymphomas].Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Bull Cancer. 2013. PMID: 23831822 Review. French.
-
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30. Oncologist. 2016. PMID: 26621039 Free PMC article.
-
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Expert Opin Investig Drugs. 2012. PMID: 22127011 Review.
-
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1. Cancer Sci. 2014. PMID: 24814862 Free PMC article. Clinical Trial.
-
Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Ann Pharmacother. 2012. PMID: 22395252 Review.
Cited by
-
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.Haematologica. 2013 Aug;98(8):1250-8. doi: 10.3324/haematol.2012.081935. Epub 2013 May 28. Haematologica. 2013. PMID: 23716562 Free PMC article.
-
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.Br J Pharmacol. 2013 Jan;168(2):445-57. doi: 10.1111/j.1476-5381.2012.02138.x. Br J Pharmacol. 2013. PMID: 22889168 Free PMC article.
-
Targeted drug delivery for cancer therapy: the other side of antibodies.J Hematol Oncol. 2012 Nov 9;5:70. doi: 10.1186/1756-8722-5-70. J Hematol Oncol. 2012. PMID: 23140144 Free PMC article. Review.
-
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy.Front Oncol. 2014 Jun 13;4:141. doi: 10.3389/fonc.2014.00141. eCollection 2014. Front Oncol. 2014. PMID: 24982846 Free PMC article. Review.
-
Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes.Theranostics. 2014 Jul 19;4(9):945-52. doi: 10.7150/thno.9246. eCollection 2014. Theranostics. 2014. PMID: 25057318 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
